Aptinyx logo
Aptinyx APTX

Quarterly report 2023-Q1
added 05-18-2023

report update icon

Aptinyx Income Statement 2011-2026 | APTX

Annual Income Statement Aptinyx

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

9.48 M 204 M 163 M 131 M 107 M - - - - - - -

Shares

67.7 M 67.2 M 47 M 33.6 M 20.2 M - - - - - - -

Historical Prices

0.14 3.04 3.66 3.22 5.3 - - - - - - -

Net Income

-64.8 M -74.9 M -50.1 M -57.4 M -53.3 M -32.1 M -15.5 M - - - - -

Revenue

- 1 M 1.56 M 3.67 M 6.57 M 4.96 M 9.79 M - - - - -

Gross Profit

- - 1.56 K - - - - - - - - -

Operating Income

-62.6 M -74.5 M -50.8 M -59.6 M -54.9 M -32.2 M - - - - - -

Interest Expense

737 K 160 K 712 K 2.2 M 1.61 M 165 K - - - - - -

EBITDA

-62.4 M -74 M -50.3 M -59.2 M -54.4 M -31.8 M -17.5 M - - - - -

Operating Expenses

62.6 M 75.5 M 52.3 M 63.3 M 61.5 M 37.2 M 27.5 M - - - - -

General and Administrative Expenses

19.8 M 20.1 M 19.5 M 19 M 12.7 M 5.55 M 4.77 M - - - - -

All numbers in USD currency

Quarterly Income Statement Aptinyx

2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

67.7 M 67.7 M 67.7 M - 67.7 M 67.7 M 67.7 M 67.4 M 66 M 63.3 M 47 M 45.7 M 43.8 M 33.7 M 33.6 M 33.5 M 33.4 M 33.3 M 33.2 M 7.28 M 5.38 M 5.34 M 5.23 M 5.16 M - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-21.1 M - -15.3 M - -19.8 M - -21.2 M -19.8 M -14.2 M - -11.3 M -12.5 M -14.7 M - -14.8 M -12.1 M -16.7 M - -14.2 M -13.3 M -11.7 M - -32.1 M -32.1 M - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - - - 1 M - 1 M - 257 K 490 K 818 K - 936 K 925 K 890 K - 943 K 2.13 M 2.46 M - 1.2 M 1.43 M - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-20.3 M - -14.7 M - -19.4 M - -21.2 M -19.9 M -14.3 M - -11.4 M -12.6 M -15.1 M - -15.3 M -12.7 M -17.3 M - -14.8 M -13.6 M -11.8 M - -8.18 M -8.04 M - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

286 K - 208 K - 29 K - 47 K 47 K 64 K - 85 K 128 K 426 K - 558 K 596 K 614 K - 608 K 245 K 137 K - 35 K 42 K - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-20.3 M - -14.5 M - -19.3 M - -20.7 M -19.8 M -13.9 M - -11.1 M -12.4 M -15 M - -15 M -12.6 M -17.2 M - -14.7 M -13.5 M -11.7 M - -8.08 M -7.94 M - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

20.3 M - 14.7 M - 19.4 M - 21.2 M 19.9 M 15.3 M - 11.7 M 13.1 M 16 M - 16.3 M 13.7 M 18.2 M - 15.7 M 15.7 M 14.3 M - 9.38 M 9.47 M - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

4.23 M - 4.65 M - 5.78 M - 4.93 M 5.07 M 4.98 M - 5.05 M 4.77 M 4.9 M - 4.52 M 4.17 M 5.72 M - 3.78 M 2.02 M 2.05 M - 1.32 M 1.27 M - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Aptinyx (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.83 2.17 % $ 4.53 M chinaChina
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 110.14 3.3 % $ 27.2 B germanyGermany
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Adagene Adagene
ADAG
$ 2.6 -1.12 % $ 146 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.51 -0.52 % $ 8.45 B australiaAustralia
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.21 1.2 % $ 9.16 B israelIsrael
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.49 7.19 % $ 279 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 221.8 -0.16 % $ 5 B danmarkDanmark
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.96 0.45 % $ 1.41 B britainBritain
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.46 2.46 % $ 373 M britainBritain
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.49 -0.24 % $ 4.48 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.35 -1.81 % $ 14.8 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA